Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Aerolife Mini, the most common co-covered peer. The 6 average consequence score is below the beat benchmark of 6.4 in the same window.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Aerolife Mini, the most common co-covered peer. The 6 average consequence score is below the beat benchmark of 6.4 in the same window. Each story carries 3 original sources on average, compared with 2.8 for the broader beat in this window. We currently track 1 Biotech story that mention AeroDel, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AeroDel. Shared-story counts are live from our verified record — not editorial picks.
AeroDel has entered into an exclusive licensing agreement with Zydus Lifesciences to launch Aerolife Mini, a first-of-its-kind foldable and permanently attached pMDI enhancer in India. This device aims to improve medication delivery and patient adherence for respiratory conditions like asthma and COPD by addressing the portability issues of traditional spacers.
AeroDel is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
